We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > COMP360

News List

NEWS Depression drug shows positive results in groundbreaking Phase IIb study EuropeanPharmaceuticalReview
November 11, 2021
COMPASS Pathways has announced that its groundbreaking Phase IIb clinical trial of COMP360 psilocybin therapy for treatment-resistant depression has achieved its primary endpoint...
COMPASS Granted Patent of Psilocybin Formulation for Treatment-Resistant Depression americanpharmaceuticalreview
January 17, 2020
COMPASS Pathways has been granted US Patent No 10,519,175, relating to methods of treating drug-resistant depression with a psilocybin formulation, by the US Patent and Trademark Office (USPTO).
Psilocybin study shows positive results in healthy volunteers europeanpharmaceuticalreview
December 16, 2019
In a new study, COMP360 (psilocybin) was well tolerated in healthy volunteers which support further investigation of a simultaneous 1:1 therapeutic administration design.